Novel approaches to the management of chronic systolic heart failure: Future directions and unanswered questions

Yogesh N.V. Reddy, Barry A. Borlaug, Christopher M. Oconnor, Bernard J. Gersh

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Despite improvements in outcomes in the last few decades for heart failure (HF) with reduced ejection fraction (HFrEF), there still remains a need for novel therapies as many patients incompletely recover with existing therapies and progress to advanced HF. In this review, we will discuss recent advances in the management of HFrEF with a focus on upcoming therapies that hold the greatest promise for clinical use. We will discuss novel pharmacological therapies and areas of uncertainty with existing therapies. We will also discuss the potential utility and controversy surrounding novel interventions for HF such as percutaneous mitral valve repair, atrial fibrillation ablation, and other emerging interventions with positive signals for benefit in HFrEF. Finally, we will summarize the current state of stem cell and gene therapy for HFrEF and future directions.

Original languageEnglish (US)
Pages (from-to)1764-1774
Number of pages11
JournalEuropean heart journal
Volume41
Issue number18
DOIs
StatePublished - May 7 2020

Keywords

  • HFrEF
  • Systolic heart failure
  • Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Novel approaches to the management of chronic systolic heart failure: Future directions and unanswered questions'. Together they form a unique fingerprint.

Cite this